Medicare

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…

6 months ago

Careington Implements Cognigy’s Voice AI Solution to Elevate Customer Service Capabilities

FRISCO, Texas, June 24, 2025 /PRNewswire/ -- Careington International Corporation is proud to announce enhanced customer service efficiencies through its collaboration…

6 months ago

CareMore Health Announces Appointment of Sam Wald as Chief Executive Officer

Wald’s history of successfully leading outcomes-focused healthcare organizations aligns with CareMore Health’s provider support and patient care prioritiesCERRITOS, Calif., June…

6 months ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025…

6 months ago

Availity Applauds Industry Commitment to Modernize Authorizations

Availity’s Intelligent Utilization Management delivers on health plans’ ambitious visionJACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity, the nation’s largest real-time health information network, celebrates…

6 months ago

GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025

GE HealthCare continues to advance precision care in cardiology through innovative molecular imaging solutions to help support early diagnosis, tailored…

6 months ago

Healthcare Financial Management Association recognizes Dan Liljenquist for contributions to healthcare

DENVER, June 23, 2025 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) presented its highest achievement award, the Richard…

6 months ago

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is…

6 months ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…

6 months ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…

6 months ago